Revolution Medicines, Inc. (RVMD) Dividend History

Revolution Medicines, Inc. (RVMD) is a biopharmaceutical company focused on developing targeted therapies for genetically driven cancers. The company specializes in designing innovative medicines aimed at specific genetic mutations involved in cancer progression, with an emphasis on solid tumors and hematologic malignancies.

700 Saginaw Dr, Redwood City, CA, 94063
Phone: 415-766-3638
Website: https://www.revmed.com

Dividend History

Revolution Medicines, Inc. currently does not pay dividends

Company News

rEvolution Appoints Brian Gabriel as Vice President of Marketing Communications

rEvolution, a global leader in sports marketing, has appointed Brian Gabriel as its new Vice President of Marketing Communications. Gabriel brings over 16 years of experience in marketing leadership across sports, CPG, and entertainment sectors, and will be responsible for developing and executing integrated marketing and communications campaigns for rEvolution's clients.

GlobeNewswire Inc.

Featured Companies: UP
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics reported its Q1 2025 financial results, highlighting progress in its PRMT5 inhibitor programs, including the ongoing TNG462 Phase 1/2 trial and plans for a combination trial with Revolution Medicines' RAS(ON) inhibitors. The company also provided updates on its other pipeline programs and extended its cash runway into Q1 2027.

GlobeNewswire Inc.

Featured Companies: TNGX
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines presented initial data from a study of its RAS(ON) G12D-selective inhibitor zoldonrasib in patients with KRAS G12D mutant non-small cell lung cancer. The data showed acceptable tolerability and encouraging initial antitumor activity.

GlobeNewswire Inc.
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter - Benzinga

Three healthcare stocks, Aveanna Healthcare Holdings Inc, Revolution Medicines, and Fulcrum Therapeutics, have seen significant price gains recently, indicating they may be overbought and could pose risks to investors focused on momentum trading.

Benzinga

Featured Companies: AVAH FULC
Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Top Wall Street analysts have updated their price targets and ratings for several major companies, including Microsoft, Revolution Medicines, Goldman Sachs, BlackRock, Starbucks, S&P Global, Profound Medical, Dollar Tree, and Shopify.

Benzinga

Featured Companies: BLK DLTR GS MSFT PROF SBUX SHOP SPGI TEAM

Dividend data last updated 06/07/2025 19:48:38 UTC